Related Experiment Video
Updated: Sep 25, 2025

Labeling of Extracellular Vesicles for Monitoring Migration and Uptake in Cartilage Explants
Published on: October 4, 2021
The Application of Extracellular Vesicles Mediated miRNAs in Osteoarthritis: Current Knowledge and Perspective
Xiaobin Shang1, Yan Fang2, Wenqiang Xin3
1Department of Orthopaedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China.
Abstract:
Osteoarthritis (OA) is a whole joint disease characterized by synovitis, cartilage destruction, and subchondral bone sclerosis and cyst. Despite decades' study, effective treatment is rare for this chronic disease. Extracellular vesicles (EVs), including exosomes, microvesicles, and apoptosis bodies, are nano-sized vesicles with a cargo containing biologically active agents, such as nucleic acids, lipids, and proteins. As a group of short non-coding RNAs, microRNAs (miRNAs) can be delivered by parental cells secreted EVs. Negatively regulate the target mRNAs at the posttranscriptional level and regulate gene expression in recipient cells without modifying gene sequence. Recently, most studies focused on the function of EVs mediated miRNAs in the pathophysiological process of OA. However, all kinds of EVs specific and OA specific factors might influence the administration of EVs-miRNAs, especially the precise quantitative management. As a result, the flourishing of current research about EVs in the laboratory might not promote the relevant clinical transformation in OA treatment. In this review, we reviewed the present application of EVs-miRNAs in the therapeutic of OA and further analyzed the potential factors that might influence its application. Further progress in the quantitative management of EVs-miRNAs would accelerate the clinical transformation of miRNAs enriched EVs in the OA field.
Insights
Extracellular vesicles (EVs) carrying microRNAs (miRNAs) show therapeutic potential for osteoarthritis (OA). Precise quantitative management of these EVs-miRNAs is crucial for advancing OA treatment from the lab to the clinic.
Area of Science:
- Biomedical Engineering
- Molecular Biology
- Regenerative Medicine
Background:
- Osteoarthritis (OA) is a degenerative joint disease with limited effective treatments.
- Extracellular vesicles (EVs) are nano-sized carriers of biologically active molecules, including microRNAs (miRNAs).
- EVs-miRNAs play a role in OA pathogenesis by regulating gene expression in recipient cells.
Purpose of the Study:
- To review the current applications of EVs-miRNAs in OA therapeutics.
- To analyze factors influencing the clinical translation of EVs-miRNA therapy for OA.
- To highlight the importance of quantitative management for advancing OA treatment.
Main Methods:
- Literature review of studies on EVs-miRNAs in osteoarthritis.
- Analysis of EV characteristics and miRNA cargo relevant to OA.
- Evaluation of challenges and opportunities for clinical application.
Main Results:
- EVs-miRNAs are investigated for their therapeutic potential in OA.
- EV specificity and precise quantitative control are key challenges.
- Current laboratory research faces hurdles in clinical transformation.
Conclusions:
- EVs-miRNAs offer a promising avenue for OA treatment.
- Overcoming challenges in quantitative management is essential for clinical success.
- Further research in precise quantification will accelerate the clinical use of EVs-miRNAs in OA.
Related Concept Videos
Mesenchymal Stem Cells
MicroRNAs
Microorganisms in Medicine and Therapeutics

